(MedPage Today) — A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients with autoimmune diseases may safely receive idecabtagene vicleucel (ide-cel; Abecma) for relapsed or refractory…
Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsmm/116052
Author :
Publish date : 2025-06-13 12:40:00
Copyright for syndicated content belongs to the linked Source.
